Join us and the FDA for a patient focused meeting on amyloidosis
Amyloidosis Research Consortium is hosting a critical meeting with the FDA in Bethesda on November 16th, 2015. This is an unprecedented opportunity: patients can inform the FDA about their experience and unmet needs. At the FDA’s request, amyloidosis experts will present the challenges of clinical trials and a pathway for promising and effective treatments to be effectively and swiftly evaluated.
This is a call for action. Admission to this meeting is free. To find out more and reserve your place, contact admin@arci.org.
- Categories
- Lastest Posts
- FDA Approves Attruby™ (acoramidis) for the Treatment of ATTR-CM: A New Option for Patients
- ARC Launches Clinical Fellowship Program to Advance Amyloidosis Care
- The More Things Change, the More They Stay the Same
- The Inflation Reduction Act: The Devil is in the Details for Patients with Rare Diseases